These adverse outcomes are attributed to effects of FGF-23 to stimulate left ventricular hypertrophy (LVH)14–16, and occur with small increments in circulating FGF-23 concentrations17,18. This evidence concerns the gene FGF23 and left ventricular hypertrophy.